Citius Pharmaceuticals/$CTXR
1D1W1MYTD1Y5YMAX
About Citius Pharmaceuticals
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
- Ticker
- $CTXR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 23
- Headquarters
- Cranford, United States
- Website
- citiuspharma.com
CTXR Metrics
BasicAdvanced
$17M
-
-$2.12
0.99
-
Price and volume
Market cap
$17M
Beta
0.99
52-week high
$2.19
52-week low
$0.47
Average daily volume
898K
Financial strength
Current ratio
0.839
Quick ratio
0.343
Long term debt to equity
9.223
Total debt to equity
9.455
Interest coverage (TTM)
-82.51%
Profitability
Gross margin (TTM)
77.34%
Net profit margin (TTM)
-651.27%
Operating margin (TTM)
-807.43%
Effective tax rate (TTM)
-0.33%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-26.57%
Return on equity (TTM)
-81.09%
Valuation
Price to revenue (TTM)
1.848
Price to book
0.25
Price to tangible book (TTM)
-0.52
Price to free cash flow (TTM)
-0.276
Free cash flow yield (TTM)
-362.65%
Free cash flow per share (TTM)
-2.183
Growth
Earnings per share change (TTM)
-55.62%
3-year earnings per share growth (CAGR)
-25.66%
10-year earnings per share growth (CAGR)
-27.88%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.